Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
EBIATLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsShares IssuedShares OutstandingShares Outstanding
Ratios

Summit Therapeutics (SMMT) Receivables - Net (2018 - 2022)

Summit Therapeutics' Receivables - Net history spans 5 years, with the latest figure at $349000.0 for Q4 2022.

  • For Q4 2022, Receivables - Net fell 76.16% year-over-year to $349000.0; the TTM value through Dec 2022 reached $349000.0, down 76.16%, while the annual FY2022 figure was $349000.0, 76.16% down from the prior year.
  • Receivables - Net reached $349000.0 in Q4 2022 per SMMT's latest filing, up from $140000.0 in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $17.3 million in Q1 2019 to a low of $140000.0 in Q3 2022.
  • Average Receivables - Net over 5 years is $4.1 million, with a median of $1.1 million recorded in 2021.
  • Peak YoY movement for Receivables - Net: crashed 96.83% in 2020, then surged 342.3% in 2021.
  • A 5-year view of Receivables - Net shows it stood at $14.9 million in 2018, then crashed by 30.16% to $10.4 million in 2019, then plummeted by 96.83% to $331000.0 in 2020, then skyrocketed by 342.3% to $1.5 million in 2021, then plummeted by 76.16% to $349000.0 in 2022.
  • Per Business Quant, the three most recent readings for SMMT's Receivables - Net are $349000.0 (Q4 2022), $140000.0 (Q3 2022), and $238000.0 (Q2 2022).